| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 598 | 2024 | 11891 | 15.590 |
Why?
|
| Acute Coronary Syndrome | 145 | 2023 | 2362 | 12.030 |
Why?
|
| Angina, Unstable | 108 | 2021 | 926 | 10.810 |
Why?
|
| Thrombolytic Therapy | 157 | 2021 | 2108 | 9.770 |
Why?
|
| Heart Failure | 243 | 2024 | 11835 | 8.090 |
Why?
|
| Cardiology | 42 | 2024 | 1723 | 7.140 |
Why?
|
| Platelet Aggregation Inhibitors | 132 | 2022 | 3201 | 6.830 |
Why?
|
| Simvastatin | 26 | 2021 | 352 | 6.290 |
Why?
|
| Coronary Disease | 171 | 2018 | 5993 | 5.450 |
Why?
|
| Pravastatin | 45 | 2016 | 393 | 5.430 |
Why?
|
| Thiazoles | 48 | 2024 | 1509 | 5.420 |
Why?
|
| Anticholesteremic Agents | 47 | 2023 | 988 | 5.350 |
Why?
|
| Pyridines | 79 | 2024 | 2877 | 5.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 71 | 2024 | 3333 | 4.840 |
Why?
|
| Cardiomyopathy, Hypertrophic | 35 | 2024 | 1300 | 4.840 |
Why?
|
| Fibrinolytic Agents | 106 | 2024 | 2167 | 4.830 |
Why?
|
| Cholesterol, LDL | 42 | 2024 | 2422 | 4.660 |
Why?
|
| Thiophenes | 39 | 2014 | 587 | 4.100 |
Why?
|
| Warfarin | 45 | 2024 | 1516 | 4.080 |
Why?
|
| Electrocardiography | 193 | 2020 | 6413 | 3.880 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 53 | 2014 | 638 | 3.710 |
Why?
|
| Angioplasty, Balloon, Coronary | 84 | 2011 | 1880 | 3.710 |
Why?
|
| Tetrazoles | 22 | 2024 | 901 | 3.680 |
Why?
|
| Atrial Fibrillation | 77 | 2024 | 5201 | 3.630 |
Why?
|
| Anticoagulants | 84 | 2024 | 4896 | 3.580 |
Why?
|
| Natriuretic Peptide, Brain | 51 | 2024 | 1705 | 3.410 |
Why?
|
| Piperazines | 53 | 2014 | 2520 | 3.400 |
Why?
|
| Heptanoic Acids | 26 | 2011 | 347 | 3.360 |
Why?
|
| Double-Blind Method | 192 | 2024 | 12412 | 3.310 |
Why?
|
| Tissue Plasminogen Activator | 68 | 2007 | 1190 | 3.160 |
Why?
|
| Angiotensin Receptor Antagonists | 23 | 2024 | 1025 | 3.080 |
Why?
|
| Enoxaparin | 30 | 2010 | 397 | 3.060 |
Why?
|
| Hemorrhage | 92 | 2024 | 3604 | 2.890 |
Why?
|
| Cardiovascular System | 8 | 2024 | 850 | 2.890 |
Why?
|
| Ticlopidine | 43 | 2015 | 895 | 2.890 |
Why?
|
| Biphenyl Compounds | 24 | 2024 | 988 | 2.650 |
Why?
|
| Stroke | 93 | 2024 | 9945 | 2.580 |
Why?
|
| Coronary Angiography | 103 | 2022 | 4560 | 2.570 |
Why?
|
| Tyrosine | 26 | 2011 | 1440 | 2.510 |
Why?
|
| Stroke Volume | 86 | 2024 | 5513 | 2.490 |
Why?
|
| Pyrroles | 26 | 2011 | 1137 | 2.460 |
Why?
|
| C-Reactive Protein | 41 | 2024 | 3822 | 2.460 |
Why?
|
| Enalapril | 11 | 2024 | 313 | 2.350 |
Why?
|
| Humans | 1159 | 2024 | 760261 | 2.350 |
Why?
|
| Neprilysin | 12 | 2024 | 472 | 2.340 |
Why?
|
| Myocardial Ischemia | 44 | 2021 | 2161 | 2.300 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 41 | 2024 | 1521 | 2.220 |
Why?
|
| Adamantane | 17 | 2021 | 169 | 2.210 |
Why?
|
| Cardiovascular Diseases | 93 | 2024 | 15740 | 2.120 |
Why?
|
| Heart | 130 | 2023 | 4392 | 2.120 |
Why?
|
| Coronary Circulation | 88 | 2012 | 1578 | 2.120 |
Why?
|
| Troponin I | 24 | 2018 | 634 | 2.080 |
Why?
|
| Dipeptides | 17 | 2021 | 410 | 2.060 |
Why?
|
| Treatment Outcome | 290 | 2024 | 64947 | 2.010 |
Why?
|
| Secondary Prevention | 49 | 2024 | 1548 | 1.980 |
Why?
|
| Acetanilides | 19 | 2014 | 169 | 1.920 |
Why?
|
| Cholesterol | 23 | 2022 | 2925 | 1.920 |
Why?
|
| Coronary Artery Disease | 35 | 2022 | 6661 | 1.890 |
Why?
|
| Peptide Fragments | 34 | 2024 | 5120 | 1.790 |
Why?
|
| Aged | 456 | 2024 | 168995 | 1.780 |
Why?
|
| Randomized Controlled Trials as Topic | 108 | 2024 | 10340 | 1.760 |
Why?
|
| Ventricular Function, Left | 36 | 2024 | 3870 | 1.750 |
Why?
|
| Middle Aged | 545 | 2024 | 220175 | 1.720 |
Why?
|
| Heparin | 41 | 2010 | 1655 | 1.720 |
Why?
|
| History, 20th Century | 40 | 2024 | 2777 | 1.710 |
Why?
|
| Drug Combinations | 29 | 2024 | 2024 | 1.700 |
Why?
|
| Myocardial Reperfusion | 24 | 2012 | 347 | 1.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 34 | 2023 | 12281 | 1.690 |
Why?
|
| Male | 653 | 2024 | 359413 | 1.680 |
Why?
|
| Ramipril | 7 | 2024 | 97 | 1.670 |
Why?
|
| Lactones | 17 | 2016 | 319 | 1.640 |
Why?
|
| Female | 649 | 2024 | 391011 | 1.630 |
Why?
|
| Drug Therapy, Combination | 76 | 2023 | 6499 | 1.620 |
Why?
|
| Coronary Artery Bypass | 42 | 2021 | 2273 | 1.600 |
Why?
|
| Angina Pectoris | 49 | 2012 | 969 | 1.580 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 22 | 2022 | 379 | 1.570 |
Why?
|
| Thrombosis | 25 | 2023 | 3052 | 1.560 |
Why?
|
| Cardiotonic Agents | 23 | 2021 | 546 | 1.550 |
Why?
|
| Myocardium | 123 | 2021 | 4688 | 1.520 |
Why?
|
| Risk Assessment | 108 | 2024 | 24086 | 1.470 |
Why?
|
| Heart Septum | 13 | 2022 | 303 | 1.410 |
Why?
|
| Dose-Response Relationship, Drug | 76 | 2024 | 10829 | 1.410 |
Why?
|
| Ventricular Dysfunction, Left | 19 | 2024 | 2129 | 1.340 |
Why?
|
| Myocardial Revascularization | 29 | 2021 | 841 | 1.340 |
Why?
|
| Biomedical Research | 15 | 2016 | 3421 | 1.340 |
Why?
|
| Adenosine | 17 | 2022 | 833 | 1.330 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 96 | 1.310 |
Why?
|
| Embolism | 16 | 2023 | 408 | 1.290 |
Why?
|
| Troponin T | 18 | 2024 | 774 | 1.270 |
Why?
|
| Aspirin | 47 | 2021 | 3365 | 1.240 |
Why?
|
| Hypolipidemic Agents | 10 | 2019 | 626 | 1.230 |
Why?
|
| Coronary Thrombosis | 15 | 2015 | 486 | 1.170 |
Why?
|
| Dyslipidemias | 4 | 2022 | 895 | 1.150 |
Why?
|
| Risk Factors | 176 | 2024 | 74269 | 1.150 |
Why?
|
| Oxygen Consumption | 67 | 2018 | 1840 | 1.150 |
Why?
|
| Plasminogen Activators | 14 | 2004 | 199 | 1.140 |
Why?
|
| Azetidines | 6 | 2015 | 137 | 1.140 |
Why?
|
| Immunoglobulin Fab Fragments | 19 | 2008 | 465 | 1.140 |
Why?
|
| Platelet Function Tests | 5 | 2008 | 303 | 1.110 |
Why?
|
| Recurrence | 81 | 2019 | 8487 | 1.110 |
Why?
|
| Atrial Natriuretic Factor | 10 | 2014 | 350 | 1.110 |
Why?
|
| Digoxin | 6 | 2017 | 247 | 1.100 |
Why?
|
| Heart Diseases | 34 | 2018 | 2809 | 1.100 |
Why?
|
| Kidney | 19 | 2023 | 7072 | 1.090 |
Why?
|
| Prognosis | 111 | 2024 | 29636 | 1.080 |
Why?
|
| Cardiovascular Agents | 15 | 2014 | 864 | 1.060 |
Why?
|
| Acute Disease | 72 | 2021 | 7268 | 1.050 |
Why?
|
| Hospitalization | 47 | 2021 | 10761 | 1.050 |
Why?
|
| Purinergic P2 Receptor Antagonists | 7 | 2011 | 72 | 1.050 |
Why?
|
| Cardiomyopathies | 10 | 2023 | 1945 | 1.050 |
Why?
|
| Vasodilator Agents | 18 | 2016 | 977 | 1.050 |
Why?
|
| Captopril | 19 | 2004 | 266 | 1.020 |
Why?
|
| Troponin | 16 | 2020 | 516 | 1.020 |
Why?
|
| Blood Platelets | 12 | 2016 | 2522 | 1.020 |
Why?
|
| Follow-Up Studies | 123 | 2021 | 39254 | 1.010 |
Why?
|
| History, 21st Century | 18 | 2016 | 1576 | 1.000 |
Why?
|
| Clinical Trials as Topic | 53 | 2024 | 8058 | 0.990 |
Why?
|
| Diuretics | 11 | 2014 | 612 | 0.990 |
Why?
|
| Drug-Eluting Stents | 8 | 2021 | 758 | 0.980 |
Why?
|
| Coronary Vessels | 63 | 2016 | 3112 | 0.980 |
Why?
|
| Hemodynamics | 113 | 2019 | 4169 | 0.960 |
Why?
|
| Time Factors | 158 | 2024 | 40133 | 0.950 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 13 | 2021 | 334 | 0.930 |
Why?
|
| Hypoglycemic Agents | 16 | 2022 | 3149 | 0.920 |
Why?
|
| Aortic Valve Stenosis | 26 | 2024 | 2064 | 0.920 |
Why?
|
| Cardiac Myosins | 1 | 2024 | 124 | 0.910 |
Why?
|
| Triglycerides | 10 | 2024 | 2476 | 0.900 |
Why?
|
| Atherosclerosis | 18 | 2024 | 3524 | 0.900 |
Why?
|
| Dogs | 153 | 2007 | 3843 | 0.900 |
Why?
|
| Myocardial Contraction | 45 | 2009 | 1516 | 0.890 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 3443 | 0.880 |
Why?
|
| Angiotensinogen | 1 | 2023 | 161 | 0.870 |
Why?
|
| Death, Sudden, Cardiac | 16 | 2024 | 1572 | 0.870 |
Why?
|
| Exercise Tolerance | 13 | 2018 | 826 | 0.870 |
Why?
|
| Myoglobin | 8 | 2006 | 159 | 0.860 |
Why?
|
| Factor XI | 1 | 2023 | 34 | 0.850 |
Why?
|
| Antithrombins | 5 | 2007 | 313 | 0.840 |
Why?
|
| Syndrome | 39 | 2008 | 3278 | 0.840 |
Why?
|
| Creatine Kinase | 38 | 2004 | 691 | 0.830 |
Why?
|
| Drug Resistance | 5 | 2008 | 1617 | 0.830 |
Why?
|
| Cardiomegaly | 28 | 2013 | 593 | 0.820 |
Why?
|
| Physiology | 14 | 2016 | 112 | 0.800 |
Why?
|
| Survival Rate | 52 | 2021 | 12806 | 0.790 |
Why?
|
| Heart Failure, Diastolic | 3 | 2018 | 77 | 0.780 |
Why?
|
| Morpholines | 7 | 2013 | 583 | 0.770 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2017 | 269 | 0.770 |
Why?
|
| Factor Xa | 4 | 2018 | 168 | 0.770 |
Why?
|
| Drug Administration Schedule | 36 | 2019 | 4900 | 0.770 |
Why?
|
| Predictive Value of Tests | 55 | 2021 | 15273 | 0.760 |
Why?
|
| Glucosides | 3 | 2024 | 536 | 0.760 |
Why?
|
| Proportional Hazards Models | 51 | 2021 | 12532 | 0.730 |
Why?
|
| Research Design | 29 | 2020 | 6181 | 0.730 |
Why?
|
| Renin-Angiotensin System | 9 | 2020 | 739 | 0.720 |
Why?
|
| Survival Analysis | 46 | 2019 | 10185 | 0.720 |
Why?
|
| Adrenergic beta-Antagonists | 31 | 2016 | 1256 | 0.710 |
Why?
|
| Administration, Oral | 29 | 2024 | 4044 | 0.710 |
Why?
|
| Diabetes Mellitus | 24 | 2023 | 5884 | 0.700 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2022 | 347 | 0.690 |
Why?
|
| Natriuretic Peptides | 5 | 2015 | 156 | 0.680 |
Why?
|
| Iron Compounds | 2 | 2017 | 28 | 0.680 |
Why?
|
| Receptor, PAR-1 | 8 | 2016 | 114 | 0.680 |
Why?
|
| Hypertension | 31 | 2023 | 8595 | 0.680 |
Why?
|
| Neopterin | 2 | 2011 | 56 | 0.670 |
Why?
|
| Creatinine | 14 | 2018 | 1906 | 0.670 |
Why?
|
| Isosorbide Dinitrate | 3 | 2016 | 37 | 0.670 |
Why?
|
| Kidney Diseases | 10 | 2022 | 2093 | 0.670 |
Why?
|
| Vascular Patency | 21 | 2016 | 901 | 0.670 |
Why?
|
| Risk | 35 | 2021 | 9629 | 0.670 |
Why?
|
| Diabetic Nephropathies | 5 | 2019 | 988 | 0.660 |
Why?
|
| Pyrrolidines | 9 | 2007 | 338 | 0.660 |
Why?
|
| Hirudin Therapy | 8 | 2002 | 43 | 0.660 |
Why?
|
| Antihypertensive Agents | 5 | 2023 | 2063 | 0.650 |
Why?
|
| Recombinant Proteins | 24 | 2013 | 6543 | 0.650 |
Why?
|
| Drug Industry | 3 | 2016 | 789 | 0.630 |
Why?
|
| Blood Pressure | 136 | 2023 | 8523 | 0.630 |
Why?
|
| Kaplan-Meier Estimate | 37 | 2017 | 6545 | 0.630 |
Why?
|
| Intracranial Hemorrhages | 16 | 2021 | 844 | 0.620 |
Why?
|
| Albuminuria | 3 | 2018 | 659 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 16 | 2018 | 7468 | 0.610 |
Why?
|
| Oximes | 8 | 2018 | 306 | 0.610 |
Why?
|
| Climate Change | 1 | 2024 | 488 | 0.610 |
Why?
|
| Platelet Aggregation | 9 | 2016 | 805 | 0.600 |
Why?
|
| Streptokinase | 16 | 2007 | 187 | 0.600 |
Why?
|
| Cardiac Output | 64 | 1986 | 837 | 0.600 |
Why?
|
| Spironolactone | 3 | 2017 | 411 | 0.590 |
Why?
|
| Benzhydryl Compounds | 4 | 2024 | 942 | 0.590 |
Why?
|
| Ischemic Preconditioning, Myocardial | 3 | 2011 | 69 | 0.580 |
Why?
|
| Angiotensins | 8 | 2024 | 143 | 0.570 |
Why?
|
| Obstetrics | 1 | 2024 | 668 | 0.560 |
Why?
|
| Prospective Studies | 71 | 2024 | 54263 | 0.550 |
Why?
|
| Diabetic Angiopathies | 7 | 2015 | 822 | 0.550 |
Why?
|
| United States | 76 | 2023 | 72363 | 0.550 |
Why?
|
| Ventricular Outflow Obstruction | 6 | 2020 | 265 | 0.550 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2019 | 435 | 0.540 |
Why?
|
| Protein Precursors | 7 | 2014 | 1135 | 0.540 |
Why?
|
| Glomerular Filtration Rate | 17 | 2023 | 2178 | 0.530 |
Why?
|
| Multivariate Analysis | 39 | 2019 | 12156 | 0.530 |
Why?
|
| Peptides | 17 | 2019 | 4358 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2023 | 2296 | 0.520 |
Why?
|
| Cholesterol, HDL | 10 | 2022 | 1817 | 0.520 |
Why?
|
| Heart Conduction System | 13 | 2004 | 1016 | 0.520 |
Why?
|
| Receptors, Angiotensin | 5 | 2024 | 141 | 0.520 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 612 | 0.510 |
Why?
|
| Thromboembolism | 6 | 2024 | 1016 | 0.510 |
Why?
|
| Heart Ventricles | 79 | 2024 | 3811 | 0.510 |
Why?
|
| Hirudins | 5 | 2006 | 194 | 0.510 |
Why?
|
| Myocardial Reperfusion Injury | 6 | 2011 | 479 | 0.510 |
Why?
|
| Stents | 16 | 2021 | 3303 | 0.510 |
Why?
|
| Heparin, Low-Molecular-Weight | 6 | 2005 | 346 | 0.510 |
Why?
|
| Circadian Rhythm | 6 | 2013 | 2567 | 0.500 |
Why?
|
| Platelet Activation | 5 | 2010 | 661 | 0.500 |
Why?
|
| Cardiac Output, Low | 5 | 2018 | 192 | 0.500 |
Why?
|
| Incidence | 41 | 2024 | 21378 | 0.500 |
Why?
|
| Coronary Care Units | 7 | 2014 | 235 | 0.490 |
Why?
|
| Arrhythmias, Cardiac | 23 | 2011 | 2255 | 0.490 |
Why?
|
| Enzyme Inhibitors | 15 | 2014 | 3726 | 0.490 |
Why?
|
| Apolipoproteins B | 3 | 2022 | 388 | 0.490 |
Why?
|
| Renal Insufficiency | 8 | 2021 | 820 | 0.490 |
Why?
|
| Awards and Prizes | 2 | 2014 | 359 | 0.490 |
Why?
|
| Rejuvenation | 1 | 2016 | 106 | 0.490 |
Why?
|
| Chemokine CCL2 | 3 | 2007 | 607 | 0.480 |
Why?
|
| Severity of Illness Index | 33 | 2019 | 15827 | 0.480 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2017 | 1520 | 0.480 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 307 | 0.480 |
Why?
|
| Benzylamines | 3 | 2024 | 248 | 0.480 |
Why?
|
| Cause of Death | 21 | 2021 | 3723 | 0.480 |
Why?
|
| Hyaluronoglucosaminidase | 27 | 1988 | 135 | 0.470 |
Why?
|
| Fluoroquinolones | 7 | 2007 | 309 | 0.470 |
Why?
|
| Oxazolidinones | 3 | 2022 | 97 | 0.470 |
Why?
|
| Heart Rate | 105 | 2016 | 4169 | 0.470 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2022 | 1004 | 0.460 |
Why?
|
| HIV | 2 | 2019 | 1579 | 0.460 |
Why?
|
| Indoles | 12 | 2019 | 1830 | 0.460 |
Why?
|
| Foundations | 1 | 2014 | 97 | 0.460 |
Why?
|
| Peripheral Arterial Disease | 9 | 2022 | 1305 | 0.460 |
Why?
|
| Interprofessional Relations | 3 | 2016 | 989 | 0.460 |
Why?
|
| Growth Differentiation Factor 15 | 5 | 2024 | 192 | 0.450 |
Why?
|
| Stem Cell Transplantation | 3 | 2018 | 1601 | 0.450 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 5 | 2017 | 103 | 0.450 |
Why?
|
| Echocardiography | 23 | 2023 | 4980 | 0.440 |
Why?
|
| Oxygen | 17 | 2016 | 4189 | 0.440 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 69 | 0.440 |
Why?
|
| Hypotension | 10 | 2023 | 883 | 0.430 |
Why?
|
| Hematinics | 1 | 2016 | 281 | 0.430 |
Why?
|
| Polymorphism, Genetic | 8 | 2009 | 4286 | 0.430 |
Why?
|
| Exercise Test | 28 | 2018 | 2125 | 0.420 |
Why?
|
| Myocardial Stunning | 4 | 2001 | 66 | 0.420 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2017 | 819 | 0.420 |
Why?
|
| Ventricular Function | 21 | 2017 | 408 | 0.420 |
Why?
|
| Blood Glucose | 12 | 2020 | 6375 | 0.420 |
Why?
|
| Patient Selection | 14 | 2022 | 4276 | 0.420 |
Why?
|
| Uracil | 2 | 2024 | 207 | 0.410 |
Why?
|
| Ventricular Septum | 2 | 2012 | 76 | 0.410 |
Why?
|
| Infusions, Intravenous | 21 | 2014 | 2235 | 0.400 |
Why?
|
| Ethanol | 2 | 2012 | 1323 | 0.400 |
Why?
|
| Comorbidity | 19 | 2019 | 10552 | 0.400 |
Why?
|
| Heart Atria | 13 | 2021 | 1344 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 19 | 2008 | 9196 | 0.400 |
Why?
|
| Physical Examination | 1 | 2018 | 1244 | 0.390 |
Why?
|
| Multicenter Studies as Topic | 20 | 2020 | 1723 | 0.390 |
Why?
|
| International Cooperation | 4 | 2014 | 1436 | 0.390 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2016 | 368 | 0.390 |
Why?
|
| Hypoglycemia | 4 | 2016 | 888 | 0.390 |
Why?
|
| Diabetes Complications | 10 | 2009 | 1342 | 0.390 |
Why?
|
| Ischemic Postconditioning | 1 | 2011 | 25 | 0.390 |
Why?
|
| Creatine Kinase, MB Form | 9 | 2018 | 211 | 0.390 |
Why?
|
| Societies, Medical | 8 | 2021 | 3903 | 0.390 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 98 | 0.390 |
Why?
|
| Patient Care Planning | 1 | 2017 | 909 | 0.390 |
Why?
|
| Hypercholesterolemia | 5 | 2016 | 1155 | 0.380 |
Why?
|
| Disease Progression | 14 | 2023 | 13505 | 0.380 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2011 | 60 | 0.380 |
Why?
|
| Odds Ratio | 25 | 2017 | 9712 | 0.380 |
Why?
|
| Blood Flow Velocity | 40 | 2005 | 1375 | 0.370 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2022 | 784 | 0.370 |
Why?
|
| Hemoglobins | 2 | 2009 | 1521 | 0.370 |
Why?
|
| Vascular Resistance | 40 | 2014 | 932 | 0.370 |
Why?
|
| Physical Exertion | 33 | 1992 | 662 | 0.370 |
Why?
|
| Benzaldehydes | 6 | 2018 | 59 | 0.370 |
Why?
|
| Animals | 220 | 2020 | 167940 | 0.370 |
Why?
|
| Blood Coagulation | 8 | 2021 | 1156 | 0.360 |
Why?
|
| Pyridones | 12 | 2011 | 788 | 0.360 |
Why?
|
| Fumarates | 2 | 2013 | 131 | 0.360 |
Why?
|
| Antifibrinolytic Agents | 2 | 2007 | 292 | 0.360 |
Why?
|
| Verapamil | 10 | 1987 | 242 | 0.360 |
Why?
|
| Propanolamines | 4 | 2001 | 162 | 0.360 |
Why?
|
| Vascular Diseases | 3 | 2018 | 1180 | 0.360 |
Why?
|
| Hypertrophy, Left Ventricular | 5 | 2024 | 853 | 0.360 |
Why?
|
| Regional Blood Flow | 32 | 2008 | 1490 | 0.360 |
Why?
|
| Defibrillators, Implantable | 4 | 2019 | 1499 | 0.350 |
Why?
|
| Hyperuricemia | 1 | 2013 | 224 | 0.350 |
Why?
|
| Forecasting | 12 | 2017 | 2931 | 0.350 |
Why?
|
| Longevity | 2 | 2017 | 1050 | 0.350 |
Why?
|
| Alanine | 9 | 2007 | 607 | 0.350 |
Why?
|
| Hyperkalemia | 3 | 2023 | 231 | 0.350 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 1500 | 0.340 |
Why?
|
| Age Factors | 32 | 2019 | 18415 | 0.340 |
Why?
|
| Lipids | 7 | 2019 | 3336 | 0.340 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 73 | 0.340 |
Why?
|
| Ablation Techniques | 1 | 2012 | 249 | 0.340 |
Why?
|
| Norepinephrine | 36 | 1986 | 900 | 0.340 |
Why?
|
| Point-of-Care Systems | 5 | 2001 | 1208 | 0.340 |
Why?
|
| Nifedipine | 9 | 1991 | 221 | 0.340 |
Why?
|
| Valine | 2 | 2013 | 409 | 0.340 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2009 | 63 | 0.340 |
Why?
|
| Necrosis | 26 | 2013 | 1612 | 0.340 |
Why?
|
| Myocarditis | 5 | 2013 | 766 | 0.340 |
Why?
|
| Polysaccharides | 1 | 2016 | 1016 | 0.330 |
Why?
|
| Heart Transplantation | 2 | 2022 | 3217 | 0.330 |
Why?
|
| Air Pollution | 1 | 2023 | 2316 | 0.330 |
Why?
|
| Air Pollutants | 1 | 2023 | 2843 | 0.330 |
Why?
|
| Isoenzymes | 16 | 2004 | 1690 | 0.330 |
Why?
|
| Aged, 80 and over | 37 | 2024 | 58947 | 0.320 |
Why?
|
| Sympathetic Nervous System | 21 | 2020 | 519 | 0.320 |
Why?
|
| Cholestyramine Resin | 1 | 2008 | 25 | 0.320 |
Why?
|
| Quality of Life | 12 | 2020 | 13300 | 0.320 |
Why?
|
| Calcium Channel Blockers | 11 | 1998 | 694 | 0.320 |
Why?
|
| Propranolol | 37 | 1988 | 489 | 0.320 |
Why?
|
| Furosemide | 4 | 2014 | 170 | 0.320 |
Why?
|
| Amides | 2 | 2013 | 448 | 0.320 |
Why?
|
| Injections, Intravenous | 20 | 2014 | 1388 | 0.310 |
Why?
|
| Drug Approval | 5 | 2019 | 816 | 0.310 |
Why?
|
| Europe | 13 | 2023 | 3433 | 0.310 |
Why?
|
| Algorithms | 10 | 2020 | 13967 | 0.310 |
Why?
|
| Isoproterenol | 29 | 1980 | 394 | 0.310 |
Why?
|
| Physicians | 4 | 2016 | 4590 | 0.310 |
Why?
|
| Lovastatin | 1 | 2008 | 116 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 1780 | 0.300 |
Why?
|
| Neurotransmitter Agents | 4 | 2008 | 661 | 0.300 |
Why?
|
| Thoracic Surgery | 13 | 2012 | 722 | 0.300 |
Why?
|
| United States Food and Drug Administration | 2 | 2015 | 1675 | 0.300 |
Why?
|
| Diagnostic Imaging | 3 | 2013 | 3526 | 0.300 |
Why?
|
| Thrombin | 4 | 2013 | 593 | 0.300 |
Why?
|
| Receptors, Thrombin | 4 | 2015 | 132 | 0.300 |
Why?
|
| Ultrasonography | 6 | 2018 | 5960 | 0.290 |
Why?
|
| Adult | 144 | 2024 | 219847 | 0.290 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 297 | 0.290 |
Why?
|
| Sex Factors | 22 | 2021 | 10530 | 0.290 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 867 | 0.280 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2016 | 150 | 0.280 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1866 | 0.280 |
Why?
|
| Career Choice | 2 | 2015 | 755 | 0.280 |
Why?
|
| Hyperemia | 2 | 2008 | 221 | 0.280 |
Why?
|
| Pulmonary Edema | 3 | 2024 | 409 | 0.280 |
Why?
|
| Carotid Sinus | 14 | 1976 | 44 | 0.280 |
Why?
|
| Endpoint Determination | 8 | 2017 | 597 | 0.280 |
Why?
|
| Mortality | 6 | 2021 | 2916 | 0.280 |
Why?
|
| Chlamydophila Infections | 2 | 2005 | 22 | 0.270 |
Why?
|
| Sulfones | 3 | 2013 | 447 | 0.270 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2011 | 253 | 0.260 |
Why?
|
| Hyperglycemia | 5 | 2013 | 1380 | 0.260 |
Why?
|
| Incretins | 2 | 2018 | 103 | 0.260 |
Why?
|
| Cerebrovascular Disorders | 7 | 2018 | 1500 | 0.260 |
Why?
|
| Atrial Function, Left | 2 | 2019 | 186 | 0.260 |
Why?
|
| Postoperative Care | 4 | 2008 | 1478 | 0.260 |
Why?
|
| Phospholipases A | 1 | 2006 | 204 | 0.250 |
Why?
|
| Natriuresis | 3 | 2002 | 105 | 0.250 |
Why?
|
| Cineangiography | 11 | 1999 | 113 | 0.250 |
Why?
|
| Analysis of Variance | 12 | 2018 | 6242 | 0.250 |
Why?
|
| Leukocyte Count | 5 | 2019 | 1600 | 0.250 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 392 | 0.250 |
Why?
|
| Prazosin | 7 | 1981 | 95 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 19 | 2018 | 3618 | 0.250 |
Why?
|
| Ouabain | 15 | 1985 | 247 | 0.250 |
Why?
|
| Heart Valve Diseases | 17 | 2017 | 1047 | 0.250 |
Why?
|
| Reflex | 10 | 1984 | 376 | 0.250 |
Why?
|
| Research Personnel | 2 | 2008 | 584 | 0.240 |
Why?
|
| Research | 15 | 2018 | 1973 | 0.240 |
Why?
|
| Renin | 7 | 2014 | 636 | 0.240 |
Why?
|
| Insulin | 16 | 2022 | 6592 | 0.240 |
Why?
|
| Shock, Cardiogenic | 11 | 2010 | 734 | 0.240 |
Why?
|
| von Willebrand Factor | 2 | 2007 | 673 | 0.240 |
Why?
|
| Potassium | 10 | 2022 | 1318 | 0.240 |
Why?
|
| Nitroglycerin | 18 | 1998 | 329 | 0.240 |
Why?
|
| Cohort Studies | 31 | 2024 | 41317 | 0.230 |
Why?
|
| HIV Infections | 3 | 2021 | 17159 | 0.230 |
Why?
|
| Pacemaker, Artificial | 12 | 2019 | 815 | 0.230 |
Why?
|
| Digitalis Glycosides | 12 | 2016 | 47 | 0.230 |
Why?
|
| Pericardium | 9 | 2021 | 675 | 0.230 |
Why?
|
| Clinical Enzyme Tests | 7 | 2011 | 114 | 0.230 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2021 | 71 | 0.230 |
Why?
|
| Barbiturates | 1 | 2024 | 113 | 0.230 |
Why?
|
| Ischemia | 10 | 2022 | 1893 | 0.230 |
Why?
|
| Health Status Indicators | 1 | 2009 | 968 | 0.230 |
Why?
|
| Lipoproteins, LDL | 5 | 2006 | 641 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 15 | 1999 | 752 | 0.220 |
Why?
|
| Combined Modality Therapy | 14 | 2009 | 8551 | 0.220 |
Why?
|
| Aortic Valve | 8 | 2023 | 1996 | 0.220 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 782 | 0.220 |
Why?
|
| Angiotensin II | 2 | 2023 | 850 | 0.220 |
Why?
|
| Chlamydophila pneumoniae | 2 | 2005 | 52 | 0.220 |
Why?
|
| Echocardiography, Doppler | 4 | 2017 | 900 | 0.220 |
Why?
|
| Heart Valve Prosthesis | 13 | 2001 | 1494 | 0.210 |
Why?
|
| Cystatin C | 4 | 2018 | 270 | 0.210 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 1109 | 0.210 |
Why?
|
| Congresses as Topic | 1 | 2008 | 804 | 0.210 |
Why?
|
| Anti-Infective Agents | 4 | 2007 | 982 | 0.210 |
Why?
|
| Serum Amyloid A Protein | 2 | 2000 | 127 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2016 | 366 | 0.210 |
Why?
|
| Death | 5 | 2020 | 678 | 0.210 |
Why?
|
| Thrombocytopenia | 3 | 2006 | 1174 | 0.210 |
Why?
|
| Chi-Square Distribution | 12 | 2012 | 3466 | 0.200 |
Why?
|
| Inflammation | 11 | 2020 | 10757 | 0.200 |
Why?
|
| Canada | 7 | 2019 | 2128 | 0.200 |
Why?
|
| Muscle Contraction | 23 | 1982 | 1201 | 0.200 |
Why?
|
| Austria | 3 | 2012 | 206 | 0.200 |
Why?
|
| Calcium | 19 | 2014 | 5726 | 0.200 |
Why?
|
| Urea | 1 | 2024 | 445 | 0.200 |
Why?
|
| History, 19th Century | 3 | 2012 | 720 | 0.200 |
Why?
|
| Liver Diseases | 3 | 2019 | 1301 | 0.200 |
Why?
|
| Piperidines | 3 | 1999 | 1650 | 0.200 |
Why?
|
| Drug Monitoring | 3 | 2018 | 966 | 0.190 |
Why?
|
| Life Tables | 4 | 2006 | 365 | 0.190 |
Why?
|
| Academic Medical Centers | 4 | 2006 | 2753 | 0.190 |
Why?
|
| Galectin 3 | 2 | 2015 | 240 | 0.190 |
Why?
|
| History, 18th Century | 2 | 2012 | 207 | 0.190 |
Why?
|
| Electric Stimulation | 25 | 1977 | 1735 | 0.190 |
Why?
|
| Guideline Adherence | 5 | 2020 | 2283 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 12 | 2020 | 5507 | 0.190 |
Why?
|
| Proline | 4 | 1985 | 457 | 0.190 |
Why?
|
| Tachycardia | 12 | 2007 | 603 | 0.190 |
Why?
|
| Safety | 6 | 2009 | 1149 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2018 | 418 | 0.190 |
Why?
|
| Metabolic Clearance Rate | 4 | 2016 | 361 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2011 | 4361 | 0.190 |
Why?
|
| Schools, Medical | 2 | 2006 | 878 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2024 | 316 | 0.190 |
Why?
|
| Patient Discharge | 6 | 2020 | 3475 | 0.180 |
Why?
|
| Ventricular Remodeling | 5 | 2013 | 1259 | 0.180 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 2002 | 0.180 |
Why?
|
| Sex Characteristics | 3 | 2019 | 2627 | 0.180 |
Why?
|
| Apolipoproteins C | 1 | 2000 | 59 | 0.180 |
Why?
|
| Syncope | 1 | 2024 | 428 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2021 | 121 | 0.180 |
Why?
|
| Primary Prevention | 3 | 2023 | 1207 | 0.180 |
Why?
|
| Angioplasty | 3 | 2012 | 360 | 0.180 |
Why?
|
| Evidence-Based Medicine | 4 | 2019 | 3696 | 0.180 |
Why?
|
| Electrocardiography, Ambulatory | 5 | 2011 | 578 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2012 | 787 | 0.180 |
Why?
|
| Statistics as Topic | 11 | 2013 | 2363 | 0.180 |
Why?
|
| Dyspnea | 5 | 2016 | 1352 | 0.180 |
Why?
|
| Apolipoproteins | 2 | 2000 | 320 | 0.180 |
Why?
|
| Cholesterol, VLDL | 1 | 2000 | 71 | 0.180 |
Why?
|
| Registries | 13 | 2017 | 8449 | 0.180 |
Why?
|
| Myocytes, Cardiac | 3 | 2014 | 1656 | 0.180 |
Why?
|
| Aldosterone | 3 | 2014 | 868 | 0.180 |
Why?
|
| Partial Thromboplastin Time | 3 | 2004 | 206 | 0.180 |
Why?
|
| Methylamines | 1 | 2021 | 138 | 0.180 |
Why?
|
| Blood Circulation | 12 | 1974 | 249 | 0.180 |
Why?
|
| Oxidative Stress | 4 | 2020 | 3107 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2024 | 516 | 0.180 |
Why?
|
| Glycine | 1 | 2003 | 663 | 0.170 |
Why?
|
| Logistic Models | 20 | 2019 | 13311 | 0.170 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1290 | 0.170 |
Why?
|
| Anistreplase | 2 | 1997 | 11 | 0.170 |
Why?
|
| Cross-Over Studies | 6 | 2019 | 2061 | 0.170 |
Why?
|
| Drug Therapy | 3 | 2021 | 504 | 0.170 |
Why?
|
| Dopamine | 7 | 2013 | 1583 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 2878 | 0.170 |
Why?
|
| American Heart Association | 3 | 2019 | 1081 | 0.170 |
Why?
|
| Carbazoles | 1 | 2001 | 221 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2018 | 515 | 0.170 |
Why?
|
| Sarcomeres | 2 | 2019 | 367 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 361 | 0.170 |
Why?
|
| Angina Pectoris, Variant | 8 | 1983 | 56 | 0.170 |
Why?
|
| Leukocytosis | 2 | 2019 | 251 | 0.170 |
Why?
|
| Body Weight | 12 | 2024 | 4613 | 0.160 |
Why?
|
| Random Allocation | 13 | 2002 | 2394 | 0.160 |
Why?
|
| Patient Compliance | 4 | 2010 | 2689 | 0.160 |
Why?
|
| Retrospective Studies | 35 | 2022 | 80301 | 0.160 |
Why?
|
| Drug Evaluation | 17 | 1992 | 642 | 0.160 |
Why?
|
| Prevalence | 9 | 2019 | 15687 | 0.160 |
Why?
|
| Lipoprotein(a) | 1 | 2024 | 499 | 0.160 |
Why?
|
| Death, Sudden | 6 | 2012 | 302 | 0.160 |
Why?
|
| Nitrites | 2 | 2018 | 159 | 0.160 |
Why?
|
| Pressoreceptors | 11 | 1976 | 100 | 0.160 |
Why?
|
| Reference Values | 7 | 2008 | 4920 | 0.160 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2020 | 124 | 0.160 |
Why?
|
| Radionuclide Imaging | 15 | 2004 | 1975 | 0.160 |
Why?
|
| Percussion | 1 | 2018 | 18 | 0.160 |
Why?
|
| Societies | 1 | 2019 | 108 | 0.160 |
Why?
|
| Coronary Vasospasm | 3 | 1983 | 83 | 0.160 |
Why?
|
| Mutation | 5 | 2019 | 29950 | 0.150 |
Why?
|
| Amiodarone | 2 | 2015 | 218 | 0.150 |
Why?
|
| Cyclic GMP | 1 | 2019 | 395 | 0.150 |
Why?
|
| Auscultation | 1 | 2018 | 38 | 0.150 |
Why?
|
| Heart Function Tests | 15 | 2004 | 319 | 0.150 |
Why?
|
| Perfusion | 15 | 1993 | 1376 | 0.150 |
Why?
|
| Metoprolol | 2 | 2016 | 92 | 0.150 |
Why?
|
| Angioplasty, Balloon | 5 | 1989 | 597 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2023 | 857 | 0.150 |
Why?
|
| Palpation | 1 | 2018 | 166 | 0.150 |
Why?
|
| Placebo Effect | 3 | 2017 | 511 | 0.150 |
Why?
|
| Quinazolines | 6 | 1986 | 1363 | 0.150 |
Why?
|
| Adolescent | 47 | 2023 | 87747 | 0.150 |
Why?
|
| Monocytes | 1 | 2007 | 2574 | 0.150 |
Why?
|
| Nobel Prize | 1 | 2018 | 48 | 0.150 |
Why?
|
| Drug Utilization | 3 | 2019 | 1195 | 0.150 |
Why?
|
| Angiocardiography | 19 | 1973 | 153 | 0.150 |
Why?
|
| Regression Analysis | 13 | 2009 | 6361 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2019 | 203 | 0.140 |
Why?
|
| Glucose | 9 | 2022 | 4361 | 0.140 |
Why?
|
| Brain Ischemia | 4 | 2016 | 3127 | 0.140 |
Why?
|
| Probability | 7 | 2010 | 2476 | 0.140 |
Why?
|
| Methoxamine | 12 | 1985 | 45 | 0.140 |
Why?
|
| Genotype | 11 | 2017 | 12959 | 0.140 |
Why?
|
| Muscular Diseases | 2 | 2017 | 551 | 0.140 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 59 | 0.140 |
Why?
|
| Anesthesiology | 1 | 2007 | 1116 | 0.140 |
Why?
|
| Nitrates | 2 | 2017 | 264 | 0.140 |
Why?
|
| Triage | 2 | 2001 | 982 | 0.140 |
Why?
|
| Education, Medical | 2 | 2008 | 1728 | 0.140 |
Why?
|
| Catecholamines | 7 | 1982 | 385 | 0.140 |
Why?
|
| Famous Persons | 1 | 2018 | 109 | 0.140 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2017 | 113 | 0.140 |
Why?
|
| Placebos | 7 | 2019 | 1672 | 0.140 |
Why?
|
| Cardiac Volume | 14 | 1985 | 199 | 0.140 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 680 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2024 | 17766 | 0.140 |
Why?
|
| Diagnosis, Differential | 8 | 2013 | 12968 | 0.130 |
Why?
|
| Italy | 2 | 2011 | 840 | 0.130 |
Why?
|
| Fibrosis | 2 | 2021 | 2042 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 3 | 2015 | 899 | 0.130 |
Why?
|
| Dobutamine | 3 | 1986 | 116 | 0.130 |
Why?
|
| Body Mass Index | 9 | 2024 | 12901 | 0.130 |
Why?
|
| Research Support as Topic | 3 | 2014 | 699 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 2017 | 155 | 0.130 |
Why?
|
| Rats, Inbred Strains | 11 | 1991 | 2094 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2019 | 615 | 0.130 |
Why?
|
| Tachycardia, Ventricular | 3 | 2011 | 1302 | 0.130 |
Why?
|
| Glyburide | 1 | 2016 | 114 | 0.130 |
Why?
|
| Aorta | 15 | 1979 | 2042 | 0.130 |
Why?
|
| Seasons | 1 | 2001 | 1523 | 0.130 |
Why?
|
| Hemofiltration | 2 | 2014 | 59 | 0.130 |
Why?
|
| Papillary Muscles | 12 | 1972 | 192 | 0.130 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20048 | 0.130 |
Why?
|
| New York | 1 | 2018 | 874 | 0.130 |
Why?
|
| Smoking | 10 | 2010 | 9070 | 0.130 |
Why?
|
| Receptors, Purinergic P2Y12 | 3 | 2011 | 124 | 0.130 |
Why?
|
| Adenosine Triphosphate | 15 | 1987 | 1995 | 0.120 |
Why?
|
| Sensitivity and Specificity | 9 | 2014 | 14656 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 20484 | 0.120 |
Why?
|
| Clinical Protocols | 3 | 2016 | 1439 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2001 | 571 | 0.120 |
Why?
|
| Case-Control Studies | 10 | 2019 | 22041 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2001 | 492 | 0.120 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 1437 | 0.120 |
Why?
|
| Adenosine Diphosphate | 4 | 2011 | 429 | 0.120 |
Why?
|
| Recreation | 1 | 2015 | 120 | 0.120 |
Why?
|
| Ethanolamines | 4 | 1981 | 155 | 0.120 |
Why?
|
| Blood Volume | 8 | 1991 | 550 | 0.120 |
Why?
|
| Milrinone | 11 | 1991 | 86 | 0.120 |
Why?
|
| Ancillary Services, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cats | 17 | 1999 | 976 | 0.120 |
Why?
|
| Emergency Medical Services | 4 | 2011 | 1927 | 0.120 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 1991 | 214 | 0.120 |
Why?
|
| Epidemiologic Methods | 3 | 2008 | 1344 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 1375 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 221 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 593 | 0.120 |
Why?
|
| Rest | 7 | 2014 | 915 | 0.120 |
Why?
|
| Ferritins | 1 | 2017 | 598 | 0.120 |
Why?
|
| Periodicals as Topic | 5 | 2016 | 1470 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2001 | 1784 | 0.120 |
Why?
|
| Glycopeptides | 2 | 2014 | 220 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2022 | 2378 | 0.110 |
Why?
|
| Metabolism | 10 | 1965 | 193 | 0.110 |
Why?
|
| Pharmacology | 10 | 1965 | 99 | 0.110 |
Why?
|
| Biological Assay | 2 | 2015 | 630 | 0.110 |
Why?
|
| RNA Interference | 1 | 2022 | 2846 | 0.110 |
Why?
|
| Ventricular Function, Right | 2 | 2017 | 610 | 0.110 |
Why?
|
| Indomethacin | 3 | 1984 | 326 | 0.110 |
Why?
|
| CD40 Ligand | 2 | 2007 | 522 | 0.110 |
Why?
|
| Natriuretic Agents | 1 | 2013 | 57 | 0.110 |
Why?
|
| Device Removal | 1 | 2019 | 634 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1991 | 326 | 0.110 |
Why?
|
| Receptors, Adrenergic | 5 | 1986 | 155 | 0.110 |
Why?
|
| Medicare | 1 | 2012 | 6771 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2020 | 3451 | 0.110 |
Why?
|
| Emergency Service, Hospital | 4 | 2012 | 7809 | 0.110 |
Why?
|
| Heart Rupture, Post-Infarction | 3 | 1990 | 48 | 0.110 |
Why?
|
| ROC Curve | 5 | 2019 | 3568 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 613 | 0.110 |
Why?
|
| Thrombophilia | 1 | 2016 | 307 | 0.110 |
Why?
|
| Hospital Mortality | 7 | 2007 | 5420 | 0.110 |
Why?
|
| Chronic Disease | 14 | 2021 | 9283 | 0.110 |
Why?
|
| Radiography | 9 | 2010 | 6965 | 0.110 |
Why?
|
| Proteinuria | 2 | 2006 | 594 | 0.110 |
Why?
|
| Electrophysiology | 5 | 2007 | 1265 | 0.110 |
Why?
|
| Catheterization | 5 | 2012 | 1432 | 0.110 |
Why?
|
| Models, Cardiovascular | 2 | 2000 | 974 | 0.110 |
Why?
|
| Coronary Stenosis | 3 | 2010 | 820 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2011 | 323 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2016 | 1755 | 0.110 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 249 | 0.110 |
Why?
|
| Prodrugs | 3 | 2009 | 259 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2000 | 1583 | 0.110 |
Why?
|
| Ultrafiltration | 1 | 2012 | 49 | 0.100 |
Why?
|
| Mitral Valve Stenosis | 13 | 2000 | 348 | 0.100 |
Why?
|
| Up-Regulation | 6 | 2018 | 4127 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 4 | 1981 | 345 | 0.100 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 211 | 0.100 |
Why?
|
| Pilot Projects | 11 | 2011 | 8553 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 1997 | 982 | 0.100 |
Why?
|
| Phosphocreatine | 7 | 1986 | 261 | 0.100 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 60 | 0.100 |
Why?
|
| Ventricular Fibrillation | 4 | 2012 | 539 | 0.100 |
Why?
|
| History, 17th Century | 1 | 2012 | 107 | 0.100 |
Why?
|
| Atropine | 14 | 1974 | 245 | 0.100 |
Why?
|
| Postoperative Complications | 12 | 2018 | 15680 | 0.100 |
Why?
|
| Patient Readmission | 6 | 2016 | 3327 | 0.100 |
Why?
|
| Purines | 4 | 2013 | 601 | 0.100 |
Why?
|
| Heart Block | 9 | 1971 | 392 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 200 | 0.100 |
Why?
|
| Adrenomedullin | 1 | 2011 | 85 | 0.100 |
Why?
|
| Aminophylline | 2 | 1981 | 41 | 0.100 |
Why?
|
| Aminopyridines | 5 | 1986 | 564 | 0.100 |
Why?
|
| History, Ancient | 1 | 2012 | 211 | 0.100 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.100 |
Why?
|
| Recovery of Function | 3 | 2019 | 2982 | 0.100 |
Why?
|
| Vasomotor System | 6 | 1986 | 207 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 5 | 2008 | 2696 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2014 | 296 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2016 | 457 | 0.100 |
Why?
|
| Metformin | 1 | 2019 | 912 | 0.100 |
Why?
|
| Phenotype | 3 | 2019 | 16543 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 177 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 143 | 0.090 |
Why?
|
| Time | 3 | 2003 | 545 | 0.090 |
Why?
|
| Factor X | 1 | 2011 | 64 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2017 | 2608 | 0.090 |
Why?
|
| Blood Proteins | 3 | 2014 | 1172 | 0.090 |
Why?
|
| Pulsatile Flow | 2 | 2004 | 320 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 2 | 2014 | 187 | 0.090 |
Why?
|
| North America | 4 | 2019 | 1282 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2017 | 976 | 0.090 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 1287 | 0.090 |
Why?
|
| Diastole | 3 | 2017 | 788 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1940 | 0.090 |
Why?
|
| Assisted Circulation | 7 | 1978 | 102 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1130 | 0.090 |
Why?
|
| Phonocardiography | 7 | 1982 | 30 | 0.090 |
Why?
|
| Methods | 16 | 1983 | 1075 | 0.090 |
Why?
|
| Obesity | 5 | 2024 | 12915 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 56 | 0.090 |
Why?
|
| Internal Medicine | 2 | 1991 | 1045 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2012 | 429 | 0.090 |
Why?
|
| Bacteria | 1 | 2021 | 2196 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2011 | 302 | 0.090 |
Why?
|
| Fluorocarbons | 4 | 1983 | 483 | 0.090 |
Why?
|
| Platelet Adhesiveness | 1 | 2010 | 154 | 0.090 |
Why?
|
| Motor Activity | 2 | 2017 | 2687 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2014 | 789 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 7803 | 0.090 |
Why?
|
| Mitochondria | 1 | 2023 | 3598 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 2469 | 0.090 |
Why?
|
| New Zealand | 2 | 2019 | 355 | 0.090 |
Why?
|
| National Socialism | 1 | 2010 | 54 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 6 | 1981 | 174 | 0.090 |
Why?
|
| Pericarditis | 2 | 1989 | 135 | 0.090 |
Why?
|
| Young Adult | 8 | 2021 | 58673 | 0.090 |
Why?
|
| Nitroprusside | 6 | 1986 | 273 | 0.080 |
Why?
|
| Methylprednisolone | 3 | 1983 | 384 | 0.080 |
Why?
|
| Drug Design | 1 | 2015 | 1062 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2013 | 2138 | 0.080 |
Why?
|
| Genetic Variation | 4 | 2015 | 6540 | 0.080 |
Why?
|
| Statistics, Nonparametric | 6 | 2009 | 2852 | 0.080 |
Why?
|
| Heart Rupture | 1 | 1989 | 21 | 0.080 |
Why?
|
| Models, Biological | 6 | 2013 | 9468 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2014 | 571 | 0.080 |
Why?
|
| Health Services Accessibility | 3 | 2002 | 5396 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2011 | 184 | 0.080 |
Why?
|
| Vocational Guidance | 1 | 2008 | 14 | 0.080 |
Why?
|
| South America | 2 | 2019 | 181 | 0.080 |
Why?
|
| Calcium Channels | 1 | 2013 | 619 | 0.080 |
Why?
|
| Rats | 25 | 1991 | 23695 | 0.080 |
Why?
|
| Diltiazem | 3 | 1992 | 131 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4109 | 0.080 |
Why?
|
| Mitral Valve Insufficiency | 12 | 2000 | 1419 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2011 | 778 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1882 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 4 | 2003 | 239 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 4357 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 5 | 1974 | 141 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2023 | 4404 | 0.080 |
Why?
|
| Treatment Failure | 5 | 2018 | 2646 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2016 | 1054 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 1987 | 241 | 0.080 |
Why?
|
| Hyperthyroidism | 4 | 1979 | 291 | 0.080 |
Why?
|
| Mesenteric Arteries | 9 | 1974 | 178 | 0.080 |
Why?
|
| Pandemics | 3 | 2020 | 8621 | 0.080 |
Why?
|
| Stimulation, Chemical | 8 | 1986 | 306 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1056 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2016 | 1132 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 2414 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2932 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3804 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 1469 | 0.070 |
Why?
|
| Proteomics | 1 | 2021 | 3810 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 14482 | 0.070 |
Why?
|
| Vitamin K | 1 | 2010 | 321 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3207 | 0.070 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2007 | 52 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 907 | 0.070 |
Why?
|
| Knowledge Bases | 1 | 2007 | 98 | 0.070 |
Why?
|
| Calgranulin A | 1 | 2007 | 80 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2008 | 195 | 0.070 |
Why?
|
| Flurbiprofen | 3 | 1981 | 21 | 0.070 |
Why?
|
| Starlings | 6 | 1964 | 7 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 395 | 0.070 |
Why?
|
| Calgranulin B | 1 | 2007 | 86 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 1997 | 1411 | 0.070 |
Why?
|
| Biopsy | 3 | 2017 | 6775 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 2 | 2010 | 113 | 0.070 |
Why?
|
| Specialization | 2 | 1991 | 779 | 0.070 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2007 | 26 | 0.070 |
Why?
|
| Prediabetic State | 1 | 2013 | 550 | 0.070 |
Why?
|
| International Normalized Ratio | 3 | 2018 | 387 | 0.070 |
Why?
|
| Lymphocytes | 3 | 2023 | 2612 | 0.070 |
Why?
|
| Sympatholytics | 6 | 1966 | 82 | 0.070 |
Why?
|
| Pulmonary Circulation | 5 | 2024 | 743 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2009 | 412 | 0.070 |
Why?
|
| Prostaglandins | 3 | 1972 | 398 | 0.070 |
Why?
|
| Ventricular Pressure | 4 | 2017 | 204 | 0.070 |
Why?
|
| Writing | 1 | 2008 | 199 | 0.070 |
Why?
|
| Australia | 2 | 2019 | 1288 | 0.070 |
Why?
|
| Heterozygote | 3 | 2008 | 2797 | 0.070 |
Why?
|
| Drug Tolerance | 6 | 1986 | 369 | 0.070 |
Why?
|
| Helminth Proteins | 1 | 2007 | 172 | 0.070 |
Why?
|
| Europe, Eastern | 2 | 2023 | 72 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2218 | 0.070 |
Why?
|
| Hydrocortisone | 7 | 1978 | 1798 | 0.070 |
Why?
|
| Age Distribution | 3 | 2017 | 2893 | 0.070 |
Why?
|
| Coronary Restenosis | 2 | 2008 | 426 | 0.070 |
Why?
|
| Injections | 3 | 2002 | 830 | 0.070 |
Why?
|
| Carbon Dioxide | 6 | 1980 | 1145 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2020 | 1038 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2006 | 197 | 0.070 |
Why?
|
| Iliac Artery | 8 | 1974 | 344 | 0.070 |
Why?
|
| Models, Statistical | 3 | 2010 | 5073 | 0.060 |
Why?
|
| Microcirculation | 7 | 2006 | 1279 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2011 | 1635 | 0.060 |
Why?
|
| Inpatients | 2 | 2012 | 2578 | 0.060 |
Why?
|
| Aryldialkylphosphatase | 1 | 2005 | 63 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2011 | 858 | 0.060 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2006 | 129 | 0.060 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3086 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 1724 | 0.060 |
Why?
|
| Pulmonary Valve Stenosis | 6 | 1974 | 172 | 0.060 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3206 | 0.060 |
Why?
|
| Reserpine | 7 | 1981 | 60 | 0.060 |
Why?
|
| Collateral Circulation | 3 | 2001 | 292 | 0.060 |
Why?
|
| Educational Status | 1 | 1993 | 2512 | 0.060 |
Why?
|
| Systole | 3 | 1985 | 947 | 0.060 |
Why?
|
| Elasticity | 7 | 1991 | 652 | 0.060 |
Why?
|
| Stem Cells | 1 | 2018 | 3525 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 859 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 1490 | 0.060 |
Why?
|
| Argentina | 1 | 2015 | 245 | 0.060 |
Why?
|
| Biliopancreatic Diversion | 1 | 2004 | 15 | 0.060 |
Why?
|
| Certification | 1 | 2008 | 423 | 0.060 |
Why?
|
| Hydroxyproline | 5 | 1985 | 110 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1395 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 629 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 2825 | 0.060 |
Why?
|
| Microscopy, Electron | 8 | 1983 | 2558 | 0.060 |
Why?
|
| Pregnancy | 4 | 2024 | 29725 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 3242 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 2008 | 539 | 0.060 |
Why?
|
| Guanethidine | 4 | 1965 | 13 | 0.060 |
Why?
|
| Timolol | 1 | 1984 | 51 | 0.060 |
Why?
|
| Enzymes | 1 | 2006 | 261 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2016 | 1577 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 1991 | 1826 | 0.060 |
Why?
|
| Decision Trees | 2 | 2001 | 506 | 0.060 |
Why?
|
| Technetium | 4 | 1980 | 321 | 0.060 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2005 | 192 | 0.060 |
Why?
|
| Arteriosclerosis | 4 | 1998 | 1064 | 0.060 |
Why?
|
| Asia | 2 | 2019 | 618 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2011 | 1395 | 0.060 |
Why?
|
| Case Management | 1 | 2006 | 273 | 0.060 |
Why?
|
| Ligation | 8 | 1984 | 448 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 551 | 0.060 |
Why?
|
| Metals | 1 | 2009 | 736 | 0.060 |
Why?
|
| Immunoassay | 3 | 2010 | 748 | 0.060 |
Why?
|
| Emergencies | 2 | 2001 | 1217 | 0.060 |
Why?
|
| Renal Artery | 7 | 1974 | 368 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 1981 | 146 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1134 | 0.060 |
Why?
|
| Premedication | 1 | 2004 | 253 | 0.060 |
Why?
|
| Heart Septal Defects, Ventricular | 6 | 1970 | 491 | 0.060 |
Why?
|
| Disease Management | 3 | 2003 | 2508 | 0.060 |
Why?
|
| Blood Pressure Determination | 9 | 1972 | 641 | 0.060 |
Why?
|
| Speech | 1 | 2008 | 548 | 0.060 |
Why?
|
| Acetates | 2 | 2011 | 322 | 0.060 |
Why?
|
| Amrinone | 5 | 1986 | 14 | 0.060 |
Why?
|
| Medicine | 2 | 1991 | 943 | 0.060 |
Why?
|
| Sodium Channel Blockers | 2 | 2014 | 172 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 422 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2006 | 536 | 0.050 |
Why?
|
| Cicatrix | 3 | 1990 | 781 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 25928 | 0.050 |
Why?
|
| Organ Size | 6 | 1991 | 2249 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 1602 | 0.050 |
Why?
|
| Pulse | 8 | 1985 | 218 | 0.050 |
Why?
|
| Gastroplasty | 1 | 2004 | 157 | 0.050 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 2135 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2006 | 422 | 0.050 |
Why?
|
| Calcinosis | 3 | 2005 | 1478 | 0.050 |
Why?
|
| Heart Septal Defects | 4 | 1965 | 191 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 840 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1297 | 0.050 |
Why?
|
| Infusions, Parenteral | 6 | 1986 | 404 | 0.050 |
Why?
|
| Ion Channels | 3 | 1982 | 1043 | 0.050 |
Why?
|
| Health Status | 4 | 2019 | 4081 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2017 | 2295 | 0.050 |
Why?
|
| Patient Admission | 2 | 2001 | 1384 | 0.050 |
Why?
|
| Sodium | 4 | 2014 | 1601 | 0.050 |
Why?
|
| Life Expectancy | 2 | 2024 | 1249 | 0.050 |
Why?
|
| Ibuprofen | 1 | 1983 | 229 | 0.050 |
Why?
|
| Angiography | 7 | 2002 | 1605 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2002 | 238 | 0.050 |
Why?
|
| Benzofurans | 1 | 1982 | 142 | 0.050 |
Why?
|
| Perhexiline | 1 | 1980 | 5 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 1503 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12602 | 0.050 |
Why?
|
| Overweight | 3 | 2019 | 2421 | 0.050 |
Why?
|
| Emergency Medicine | 1 | 2010 | 1195 | 0.050 |
Why?
|
| Latin America | 2 | 2018 | 405 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4437 | 0.050 |
Why?
|
| Constriction, Pathologic | 13 | 1994 | 1098 | 0.050 |
Why?
|
| Linear Models | 4 | 2012 | 5876 | 0.050 |
Why?
|
| Outpatients | 3 | 2014 | 1606 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6830 | 0.050 |
Why?
|
| Mitral Valve | 8 | 1997 | 1486 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 200 | 0.050 |
Why?
|
| Fibrinolysis | 3 | 2010 | 332 | 0.050 |
Why?
|
| Demography | 2 | 2003 | 1650 | 0.050 |
Why?
|
| Motivation | 2 | 2008 | 1990 | 0.050 |
Why?
|
| Bundle-Branch Block | 4 | 1988 | 281 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2011 | 1992 | 0.040 |
Why?
|
| Sirolimus | 1 | 2007 | 1548 | 0.040 |
Why?
|
| Survivors | 2 | 2008 | 2367 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 1726 | 0.040 |
Why?
|
| Body Constitution | 1 | 2000 | 273 | 0.040 |
Why?
|
| Nadroparin | 1 | 1999 | 3 | 0.040 |
Why?
|
| Propionates | 1 | 1981 | 182 | 0.040 |
Why?
|
| Neoplasms | 3 | 2018 | 22066 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1207 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2009 | 2441 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2010 | 2609 | 0.040 |
Why?
|
| Internationality | 2 | 2016 | 1005 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2007 | 1738 | 0.040 |
Why?
|
| Phentolamine | 6 | 1981 | 102 | 0.040 |
Why?
|
| Heart Injuries | 2 | 1980 | 208 | 0.040 |
Why?
|
| Phenylephrine | 6 | 1976 | 293 | 0.040 |
Why?
|
| Serum Albumin | 3 | 2016 | 674 | 0.040 |
Why?
|
| Urine | 3 | 2013 | 363 | 0.040 |
Why?
|
| P-Selectin | 2 | 2000 | 600 | 0.040 |
Why?
|
| Dalteparin | 1 | 1999 | 44 | 0.040 |
Why?
|
| Equipment Design | 1 | 2008 | 3520 | 0.040 |
Why?
|
| Digitalis | 3 | 1964 | 14 | 0.040 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 138 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 3 | 1998 | 2660 | 0.040 |
Why?
|
| Government Agencies | 1 | 2000 | 161 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2002 | 460 | 0.040 |
Why?
|
| Geography | 1 | 2001 | 661 | 0.040 |
Why?
|
| Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
| Apolipoprotein C-III | 1 | 2000 | 209 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 319 | 0.040 |
Why?
|
| Extremities | 2 | 2016 | 867 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2009 | 3257 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2022 | 475 | 0.040 |
Why?
|
| France | 2 | 2011 | 511 | 0.040 |
Why?
|
| Tyramine | 4 | 1968 | 53 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 680 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 1980 | 245 | 0.040 |
Why?
|
| Heart Defects, Congenital | 11 | 1984 | 4668 | 0.040 |
Why?
|
| Diet | 2 | 2017 | 8008 | 0.040 |
Why?
|
| Anemia | 2 | 2005 | 1511 | 0.040 |
Why?
|
| Benzazepines | 1 | 1980 | 311 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3784 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2002 | 625 | 0.040 |
Why?
|
| Disease Models, Animal | 14 | 1985 | 18134 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2022 | 882 | 0.040 |
Why?
|
| Ferricyanides | 1 | 1978 | 31 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2000 | 364 | 0.040 |
Why?
|
| Phospholipids | 1 | 2022 | 789 | 0.040 |
Why?
|
| Radioisotopes | 3 | 1987 | 495 | 0.040 |
Why?
|
| Strophanthins | 4 | 1969 | 5 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 1999 | 679 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2019 | 122 | 0.040 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 1969 | 30 | 0.040 |
Why?
|
| Length of Stay | 3 | 1998 | 6472 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2002 | 549 | 0.040 |
Why?
|
| Selection Bias | 2 | 1997 | 358 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 652 | 0.040 |
Why?
|
| Rheology | 2 | 2000 | 348 | 0.040 |
Why?
|
| Biological Availability | 1 | 1998 | 395 | 0.040 |
Why?
|
| Hormones | 1 | 1981 | 867 | 0.040 |
Why?
|
| Child | 25 | 2019 | 79758 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 759 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 1981 | 482 | 0.040 |
Why?
|
| Vasodilation | 4 | 1986 | 964 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 6 | 2000 | 584 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2178 | 0.040 |
Why?
|
| Women's Health | 1 | 2007 | 2057 | 0.040 |
Why?
|
| Walking | 2 | 2015 | 1190 | 0.040 |
Why?
|
| Denervation | 3 | 1976 | 277 | 0.040 |
Why?
|
| Fibrinopeptide A | 1 | 1996 | 43 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2019 | 251 | 0.040 |
Why?
|
| Autoradiography | 3 | 1983 | 730 | 0.040 |
Why?
|
| Arteries | 6 | 1993 | 1126 | 0.030 |
Why?
|
| Serum Albumin, Radio-Iodinated | 3 | 1971 | 37 | 0.030 |
Why?
|
| Protein-Losing Enteropathies | 2 | 1968 | 45 | 0.030 |
Why?
|
| Pulmonary Artery | 11 | 1972 | 1919 | 0.030 |
Why?
|
| Germany | 1 | 2019 | 875 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1697 | 0.030 |
Why?
|
| Constriction | 6 | 1981 | 171 | 0.030 |
Why?
|
| Free Radicals | 2 | 1988 | 238 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2002 | 615 | 0.030 |
Why?
|
| Antithrombin III | 1 | 1996 | 129 | 0.030 |
Why?
|
| Communication | 2 | 2008 | 3846 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 3 | 1985 | 334 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 173 | 0.030 |
Why?
|
| Forearm | 3 | 1969 | 429 | 0.030 |
Why?
|
| Transferrin | 1 | 2017 | 284 | 0.030 |
Why?
|
| Prothrombin | 1 | 1996 | 191 | 0.030 |
Why?
|
| Retreatment | 2 | 2012 | 600 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 261 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2004 | 826 | 0.030 |
Why?
|
| Muscles | 3 | 1974 | 1581 | 0.030 |
Why?
|
| Cytokines | 2 | 2001 | 7345 | 0.030 |
Why?
|
| Posture | 5 | 1980 | 954 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 5 | 1968 | 167 | 0.030 |
Why?
|
| Niacin | 1 | 2016 | 119 | 0.030 |
Why?
|
| Brazil | 1 | 2019 | 1214 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1987 | 3561 | 0.030 |
Why?
|
| Exercise | 4 | 2010 | 5783 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 1156 | 0.030 |
Why?
|
| Health Services | 1 | 1980 | 754 | 0.030 |
Why?
|
| Long-Term Care | 2 | 2015 | 628 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1980 | 749 | 0.030 |
Why?
|
| Curriculum | 2 | 2008 | 3722 | 0.030 |
Why?
|
| Mathematics | 3 | 1985 | 708 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1995 | 866 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.030 |
Why?
|
| Dilatation | 3 | 1988 | 307 | 0.030 |
Why?
|
| Thallium | 2 | 1987 | 100 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2018 | 8018 | 0.030 |
Why?
|
| Heart Septal Defects, Atrial | 3 | 1967 | 461 | 0.030 |
Why?
|
| Weight Loss | 3 | 2012 | 2683 | 0.030 |
Why?
|
| Indicator Dilution Techniques | 2 | 1966 | 43 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 1998 | 579 | 0.030 |
Why?
|
| Training Support | 1 | 1975 | 107 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1997 | 366 | 0.030 |
Why?
|
| Vascular Grafting | 1 | 2016 | 153 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1997 | 865 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2016 | 491 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1995 | 280 | 0.030 |
Why?
|
| Heart, Artificial | 2 | 1964 | 107 | 0.030 |
Why?
|
| Cold Temperature | 3 | 1976 | 780 | 0.030 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2000 | 355 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2016 | 466 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1986 | 2359 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2001 | 2668 | 0.030 |
Why?
|
| Informed Consent | 1 | 2020 | 1007 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 1189 | 0.030 |
Why?
|
| Radiography, Thoracic | 3 | 1964 | 1295 | 0.030 |
Why?
|
| Polymers | 1 | 1981 | 1620 | 0.030 |
Why?
|
| Amino Alcohols | 1 | 1973 | 19 | 0.030 |
Why?
|
| Hospital Departments | 1 | 1993 | 136 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 1201 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 1996 | 623 | 0.030 |
Why?
|
| Pyridazines | 2 | 1986 | 200 | 0.030 |
Why?
|
| Adrenergic Agents | 2 | 1963 | 74 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 81216 | 0.030 |
Why?
|
| Platelet Count | 2 | 2006 | 777 | 0.030 |
Why?
|
| Rats, Mutant Strains | 2 | 1982 | 60 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 280 | 0.030 |
Why?
|
| Depression, Chemical | 4 | 1982 | 185 | 0.030 |
Why?
|
| Plasminogen | 2 | 1990 | 146 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 221 | 0.030 |
Why?
|
| Blood Gas Analysis | 2 | 1982 | 379 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2013 | 163 | 0.030 |
Why?
|
| Aorta, Thoracic | 3 | 1971 | 1097 | 0.030 |
Why?
|
| Procollagen | 1 | 2012 | 188 | 0.030 |
Why?
|
| Contrast Media | 3 | 2001 | 5301 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1993 | 270 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2000 | 1689 | 0.020 |
Why?
|
| Spectrophotometry | 3 | 1972 | 311 | 0.020 |
Why?
|
| Kymography | 1 | 1971 | 12 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 4409 | 0.020 |
Why?
|
| Radar | 1 | 1971 | 11 | 0.020 |
Why?
|
| Radionuclide Ventriculography | 1 | 1991 | 40 | 0.020 |
Why?
|
| Pressure | 5 | 1978 | 1155 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 5 | 1988 | 1628 | 0.020 |
Why?
|
| Guinea Pigs | 4 | 1980 | 1314 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2002 | 5201 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 3 | 1990 | 1799 | 0.020 |
Why?
|
| Mitochondria, Heart | 3 | 1982 | 229 | 0.020 |
Why?
|
| Ultrasonics | 4 | 1974 | 207 | 0.020 |
Why?
|
| Financing, Government | 1 | 1975 | 472 | 0.020 |
Why?
|
| Pathology | 2 | 1964 | 270 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1995 | 3086 | 0.020 |
Why?
|
| Cardiac Care Facilities | 1 | 1990 | 34 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 1986 | 178 | 0.020 |
Why?
|
| Health Behavior | 1 | 2002 | 2621 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 1983 | 227 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2009 | 2783 | 0.020 |
Why?
|
| Exercise Therapy | 2 | 1980 | 920 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 951 | 0.020 |
Why?
|
| Norway | 1 | 2012 | 497 | 0.020 |
Why?
|
| Fibrinogen | 2 | 1991 | 887 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3770 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 1032 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 707 | 0.020 |
Why?
|
| Alleles | 1 | 2001 | 6900 | 0.020 |
Why?
|
| Patients | 2 | 2001 | 906 | 0.020 |
Why?
|
| Brachial Artery | 3 | 1971 | 368 | 0.020 |
Why?
|
| Causality | 1 | 2016 | 1241 | 0.020 |
Why?
|
| Anesthesia, General | 3 | 1971 | 1165 | 0.020 |
Why?
|
| Cyclic AMP | 2 | 1986 | 1455 | 0.020 |
Why?
|
| Autonomic Nerve Block | 2 | 1970 | 81 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 165 | 0.020 |
Why?
|
| Fluids and Secretions | 2 | 1965 | 6 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 722 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 2 | 1968 | 265 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2009 | 173 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 1990 | 156 | 0.020 |
Why?
|
| Postmenopause | 1 | 1998 | 2503 | 0.020 |
Why?
|
| Spasm | 2 | 1980 | 131 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 711 | 0.020 |
Why?
|
| Arrhythmia, Sinus | 2 | 1968 | 48 | 0.020 |
Why?
|
| Glucagon | 3 | 1986 | 532 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1975 | 693 | 0.020 |
Why?
|
| Action Potentials | 3 | 1982 | 1814 | 0.020 |
Why?
|
| Bradycardia | 2 | 1986 | 298 | 0.020 |
Why?
|
| Pericarditis, Constrictive | 2 | 1968 | 46 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 1993 | 1166 | 0.020 |
Why?
|
| Fasting | 1 | 2015 | 1603 | 0.020 |
Why?
|
| Vena Cava, Inferior | 4 | 1974 | 458 | 0.020 |
Why?
|
| Dye Dilution Technique | 2 | 1967 | 17 | 0.020 |
Why?
|
| Nerve Endings | 2 | 1968 | 105 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7854 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 1990 | 367 | 0.020 |
Why?
|
| Prosthesis Design | 2 | 2009 | 2127 | 0.020 |
Why?
|
| Epinephrine | 3 | 1974 | 791 | 0.020 |
Why?
|
| Plethysmography | 2 | 1968 | 174 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2016 | 1196 | 0.020 |
Why?
|
| Phenoxybenzamine | 2 | 1981 | 53 | 0.020 |
Why?
|
| Receptors, Lipoprotein | 1 | 1988 | 88 | 0.020 |
Why?
|
| Leukopenia | 1 | 1968 | 212 | 0.020 |
Why?
|
| Eating | 1 | 1974 | 1538 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 604 | 0.020 |
Why?
|
| Thrombophlebitis | 2 | 1968 | 289 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 11902 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3737 | 0.020 |
Why?
|
| Massachusetts | 2 | 2014 | 8805 | 0.020 |
Why?
|
| Progesterone Congeners | 1 | 2007 | 44 | 0.020 |
Why?
|
| Lidocaine | 1 | 1990 | 538 | 0.020 |
Why?
|
| Electric Countershock | 2 | 1973 | 537 | 0.020 |
Why?
|
| Telemetry | 3 | 1972 | 199 | 0.020 |
Why?
|
| Hypothyroidism | 2 | 1969 | 665 | 0.020 |
Why?
|
| Synaptic Transmission | 2 | 1974 | 1169 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2007 | 253 | 0.020 |
Why?
|
| Mitochondria, Muscle | 3 | 1974 | 172 | 0.020 |
Why?
|
| Tricuspid Valve | 2 | 1972 | 409 | 0.020 |
Why?
|
| Cardanolides | 4 | 1971 | 4 | 0.020 |
Why?
|
| Radiometry | 2 | 1962 | 813 | 0.020 |
Why?
|
| Oxyfedrine | 1 | 1986 | 1 | 0.020 |
Why?
|
| Enoximone | 1 | 1986 | 9 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7400 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1986 | 34 | 0.020 |
Why?
|
| Decision Making | 1 | 2000 | 3924 | 0.020 |
Why?
|
| Uric Acid | 1 | 2012 | 807 | 0.020 |
Why?
|
| Pulmonary Embolism | 3 | 1988 | 2544 | 0.020 |
Why?
|
| Vectorcardiography | 2 | 1956 | 48 | 0.020 |
Why?
|
| Valsalva Maneuver | 3 | 1970 | 98 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2013 | 1100 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2000 | 23363 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1986 | 56 | 0.020 |
Why?
|
| Life Style | 1 | 2017 | 3888 | 0.020 |
Why?
|
| Theophylline | 1 | 1986 | 131 | 0.020 |
Why?
|
| Xanthines | 1 | 1986 | 122 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2009 | 1174 | 0.020 |
Why?
|
| Pentobarbital | 3 | 1971 | 153 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 2 | 1980 | 262 | 0.020 |
Why?
|
| Coenzymes | 1 | 1986 | 102 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2017 | 2163 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 2918 | 0.020 |
Why?
|
| Infant | 7 | 2021 | 36030 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 1266 | 0.020 |
Why?
|
| Anaerobiosis | 2 | 1976 | 139 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4492 | 0.020 |
Why?
|
| Vagotomy | 1 | 1965 | 83 | 0.020 |
Why?
|
| Reoperation | 1 | 1995 | 4292 | 0.020 |
Why?
|
| Respiration | 3 | 1969 | 1648 | 0.020 |
Why?
|
| Amyl Nitrite | 1 | 1964 | 7 | 0.020 |
Why?
|
| Levodopa | 1 | 1986 | 217 | 0.020 |
Why?
|
| Hypoxanthines | 2 | 1984 | 35 | 0.020 |
Why?
|
| Chromatography | 1 | 1964 | 189 | 0.020 |
Why?
|
| Blood Vessels | 3 | 1982 | 1112 | 0.020 |
Why?
|
| Oklahoma | 1 | 2004 | 36 | 0.020 |
Why?
|
| Calcium Chloride | 1 | 1964 | 78 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 1426 | 0.020 |
Why?
|
| Mephentermine | 2 | 1961 | 6 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 877 | 0.010 |
Why?
|
| Glycogen | 3 | 1978 | 251 | 0.010 |
Why?
|
| Ubiquinone | 1 | 1986 | 183 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 9497 | 0.010 |
Why?
|
| Heart Auscultation | 1 | 1964 | 34 | 0.010 |
Why?
|
| Tritium | 1 | 1964 | 707 | 0.010 |
Why?
|
| Sensory Receptor Cells | 2 | 1970 | 509 | 0.010 |
Why?
|
| Metaraminol | 1 | 1963 | 8 | 0.010 |
Why?
|
| Photomicrography | 1 | 1964 | 71 | 0.010 |
Why?
|
| Hemothorax | 1 | 1964 | 57 | 0.010 |
Why?
|
| Autonomic Nervous System | 2 | 1971 | 697 | 0.010 |
Why?
|
| Histamine | 1 | 1986 | 499 | 0.010 |
Why?
|
| Inosine | 2 | 1984 | 130 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1181 | 0.010 |
Why?
|
| Neurochemistry | 1 | 1963 | 29 | 0.010 |
Why?
|
| Situs Inversus | 1 | 1964 | 63 | 0.010 |
Why?
|
| Minoxidil | 1 | 1984 | 34 | 0.010 |
Why?
|
| Transferases | 1 | 1963 | 72 | 0.010 |
Why?
|
| Neurophysiology | 1 | 1964 | 144 | 0.010 |
Why?
|
| Disease | 3 | 1958 | 671 | 0.010 |
Why?
|
| Postoperative Period | 2 | 1986 | 1821 | 0.010 |
Why?
|
| Hemostasis | 2 | 1996 | 468 | 0.010 |
Why?
|
| Embolism, Air | 1 | 1964 | 110 | 0.010 |
Why?
|
| Biochemical Phenomena | 1 | 1963 | 58 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 1679 | 0.010 |
Why?
|
| SRS-A | 1 | 1983 | 133 | 0.010 |
Why?
|
| Reference Standards | 1 | 2007 | 1004 | 0.010 |
Why?
|
| Anesthesia | 2 | 1972 | 1584 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1963 | 178 | 0.010 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 1963 | 27 | 0.010 |
Why?
|
| Endocardium | 2 | 1983 | 246 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1990 | 1297 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2004 | 615 | 0.010 |
Why?
|
| Tricuspid Atresia | 1 | 1963 | 37 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 1977 | 404 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 2 | 1978 | 917 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 2 | 2000 | 182 | 0.010 |
Why?
|
| Albumins | 2 | 1980 | 577 | 0.010 |
Why?
|
| Biochemistry | 1 | 1963 | 114 | 0.010 |
Why?
|
| Fees, Pharmaceutical | 1 | 2002 | 66 | 0.010 |
Why?
|
| Heart Sounds | 1 | 1962 | 17 | 0.010 |
Why?
|
| Artificial Organs | 1 | 1964 | 149 | 0.010 |
Why?
|
| Residual Volume | 1 | 1962 | 41 | 0.010 |
Why?
|
| Glutamine | 1 | 2005 | 576 | 0.010 |
Why?
|
| Magnetics | 3 | 1970 | 600 | 0.010 |
Why?
|
| Adenosine Monophosphate | 2 | 1984 | 283 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2012 | 3514 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1983 | 383 | 0.010 |
Why?
|
| Fluorescence | 1 | 1964 | 750 | 0.010 |
Why?
|
| Data Collection | 2 | 2001 | 3317 | 0.010 |
Why?
|
| Immunity | 1 | 1968 | 998 | 0.010 |
Why?
|
| Pulmonary Valve | 1 | 1966 | 414 | 0.010 |
Why?
|
| Hepatitis | 1 | 1964 | 231 | 0.010 |
Why?
|
| Chest Pain | 1 | 2009 | 1106 | 0.010 |
Why?
|
| Thorax | 3 | 1978 | 553 | 0.010 |
Why?
|
| Teprotide | 1 | 1981 | 25 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 934 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 1964 | 336 | 0.010 |
Why?
|
| Antigens, Human Platelet | 1 | 2001 | 41 | 0.010 |
Why?
|
| Hydralazine | 1 | 1981 | 36 | 0.010 |
Why?
|
| Sodium, Dietary | 1 | 1965 | 425 | 0.010 |
Why?
|
| Ergonovine | 1 | 1981 | 14 | 0.010 |
Why?
|
| Biological Transport | 2 | 1982 | 2087 | 0.010 |
Why?
|
| Drug Costs | 1 | 2009 | 1184 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1984 | 1121 | 0.010 |
Why?
|
| Critical Care | 1 | 1994 | 2699 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1981 | 89 | 0.010 |
Why?
|
| Concurrent Review | 1 | 1980 | 13 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13456 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1980 | 114 | 0.010 |
Why?
|
| Tetralogy of Fallot | 2 | 1964 | 631 | 0.010 |
Why?
|
| Employee Incentive Plans | 1 | 1980 | 15 | 0.010 |
Why?
|
| Preoperative Care | 3 | 1980 | 2255 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1986 | 623 | 0.010 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1962 | 160 | 0.010 |
Why?
|
| Polarography | 2 | 1971 | 10 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2008 | 3605 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 1786 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 1981 | 110 | 0.010 |
Why?
|
| Partial Pressure | 3 | 1979 | 245 | 0.010 |
Why?
|
| Veins | 2 | 1966 | 765 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1964 | 522 | 0.010 |
Why?
|
| Sulfinpyrazone | 1 | 1980 | 15 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1980 | 5867 | 0.010 |
Why?
|
| Oximetry | 3 | 1970 | 461 | 0.010 |
Why?
|
| Hematocrit | 1 | 1982 | 630 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 17628 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1987 | 1534 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 1520 | 0.010 |
Why?
|
| Imidazoles | 1 | 1986 | 1178 | 0.010 |
Why?
|
| Energy Metabolism | 2 | 1981 | 2869 | 0.010 |
Why?
|
| Transposition of Great Vessels | 1 | 1964 | 590 | 0.010 |
Why?
|
| Child, Preschool | 11 | 1972 | 42034 | 0.010 |
Why?
|
| Glycolysis | 2 | 1974 | 828 | 0.010 |
Why?
|
| Nitrogen | 1 | 1980 | 350 | 0.010 |
Why?
|
| Hot Temperature | 2 | 1981 | 1435 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2013 | 3960 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 2 | 1974 | 495 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1988 | 2141 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 15766 | 0.010 |
Why?
|
| Hypertrophy | 2 | 1972 | 555 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3531 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2010 | 2064 | 0.010 |
Why?
|
| Biological Products | 1 | 1988 | 914 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1981 | 2186 | 0.010 |
Why?
|
| Electricity | 2 | 1969 | 182 | 0.010 |
Why?
|
| Ileum | 1 | 1981 | 556 | 0.010 |
Why?
|
| Sphygmomanometers | 1 | 1997 | 19 | 0.010 |
Why?
|
| Lipid Metabolism | 2 | 1980 | 1902 | 0.010 |
Why?
|
| Electrodes, Implanted | 2 | 1974 | 833 | 0.010 |
Why?
|
| Sleep | 2 | 1971 | 4746 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1705 | 0.010 |
Why?
|
| Particle Size | 1 | 1982 | 1643 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1981 | 592 | 0.010 |
Why?
|
| Feces | 1 | 1964 | 1466 | 0.010 |
Why?
|
| Endothelium | 1 | 1980 | 764 | 0.010 |
Why?
|
| Mitochondrial Swelling | 2 | 1978 | 16 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8314 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1978 | 92 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1964 | 736 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1971 | 629 | 0.010 |
Why?
|
| Extracorporeal Circulation | 2 | 1968 | 182 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2009 | 1938 | 0.010 |
Why?
|
| Mannitol | 1 | 1978 | 180 | 0.010 |
Why?
|
| Carotid Arteries | 2 | 1972 | 951 | 0.010 |
Why?
|
| Atrial Appendage | 1 | 1961 | 292 | 0.010 |
Why?
|
| Cell Survival | 2 | 1980 | 5796 | 0.010 |
Why?
|
| Rabbits | 2 | 1975 | 4773 | 0.010 |
Why?
|
| Testis | 1 | 1981 | 794 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1977 | 116 | 0.010 |
Why?
|
| Diphosphates | 1 | 1977 | 84 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 1976 | 82 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1982 | 1484 | 0.010 |
Why?
|
| Muscle Proteins | 2 | 1974 | 1152 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1981 | 1188 | 0.010 |
Why?
|
| Bioprosthesis | 1 | 2000 | 599 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 1666 | 0.010 |
Why?
|
| Cardiac Complexes, Premature | 2 | 1977 | 63 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1977 | 393 | 0.010 |
Why?
|
| Skin | 1 | 1969 | 4468 | 0.010 |
Why?
|
| Vagus Nerve | 2 | 1970 | 457 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 11341 | 0.010 |
Why?
|
| Organization and Administration | 1 | 1975 | 54 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2005 | 1915 | 0.010 |
Why?
|
| Medical Records | 1 | 1980 | 1407 | 0.010 |
Why?
|
| Cattle | 1 | 1981 | 3847 | 0.010 |
Why?
|
| Autopsy | 2 | 1984 | 1007 | 0.010 |
Why?
|
| Cardiovascular Abnormalities | 1 | 1955 | 143 | 0.010 |
Why?
|
| Central Nervous System | 2 | 1974 | 1334 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 21065 | 0.010 |
Why?
|
| Venous Pressure | 1 | 1974 | 57 | 0.010 |
Why?
|
| Phenethylamines | 1 | 1974 | 95 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2002 | 1192 | 0.010 |
Why?
|
| Sinoatrial Node | 1 | 1974 | 99 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13249 | 0.010 |
Why?
|
| Kinetics | 1 | 1981 | 6378 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3389 | 0.010 |
Why?
|
| Cerebral Ventriculography | 1 | 1973 | 44 | 0.010 |
Why?
|
| Proteins | 2 | 1968 | 6030 | 0.010 |
Why?
|
| Health Planning | 1 | 1975 | 232 | 0.010 |
Why?
|
| Patient Transfer | 2 | 1990 | 778 | 0.010 |
Why?
|
| Lactates | 1 | 1974 | 404 | 0.010 |
Why?
|
| Vitamin D | 1 | 2007 | 3293 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1973 | 194 | 0.010 |
Why?
|
| Propantheline | 1 | 1972 | 6 | 0.010 |
Why?
|
| Chemoreceptor Cells | 2 | 1973 | 89 | 0.010 |
Why?
|
| Peer Review | 1 | 1975 | 218 | 0.010 |
Why?
|
| Academies and Institutes | 1 | 1975 | 319 | 0.010 |
Why?
|
| Myofibrils | 1 | 1973 | 141 | 0.010 |
Why?
|
| Quinidine | 1 | 1972 | 52 | 0.010 |
Why?
|
| Leg | 4 | 1971 | 1091 | 0.010 |
Why?
|
| Electromagnetic Phenomena | 1 | 1973 | 161 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 9336 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1972 | 197 | 0.010 |
Why?
|
| Aging | 2 | 1982 | 8641 | 0.010 |
Why?
|
| Myography | 1 | 1972 | 111 | 0.010 |
Why?
|
| Ovulation | 1 | 1972 | 181 | 0.010 |
Why?
|
| Temperature | 2 | 1969 | 2221 | 0.010 |
Why?
|
| Digestive System | 1 | 1972 | 244 | 0.010 |
Why?
|
| Heart-Lung Machine | 1 | 1971 | 44 | 0.010 |
Why?
|
| Bretylium Compounds | 1 | 1971 | 7 | 0.010 |
Why?
|
| Ilium | 1 | 1972 | 154 | 0.010 |
Why?
|
| Manometry | 1 | 1974 | 453 | 0.010 |
Why?
|
| Mesentery | 1 | 1972 | 203 | 0.010 |
Why?
|
| Mesenteric Veins | 1 | 1971 | 83 | 0.010 |
Why?
|
| Venae Cavae | 1 | 1970 | 41 | 0.010 |
Why?
|
| Iliac Vein | 1 | 1971 | 70 | 0.010 |
Why?
|
| Renal Veins | 1 | 1971 | 102 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1971 | 160 | 0.010 |
Why?
|
| Genital Diseases, Female | 1 | 1972 | 191 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1977 | 2222 | 0.010 |
Why?
|
| Blood Protein Disorders | 1 | 1970 | 9 | 0.010 |
Why?
|
| Transducers | 1 | 1972 | 240 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1970 | 151 | 0.010 |
Why?
|
| Menstruation | 1 | 1972 | 307 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1974 | 651 | 0.010 |
Why?
|
| Feedback | 1 | 1974 | 791 | 0.010 |
Why?
|
| Brachiocephalic Veins | 1 | 1970 | 21 | 0.010 |
Why?
|
| Embryo Implantation | 1 | 1972 | 270 | 0.010 |
Why?
|
| Neural Inhibition | 1 | 1974 | 589 | 0.010 |
Why?
|
| Phenols | 1 | 1974 | 513 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1974 | 924 | 0.010 |
Why?
|
| Sepsis | 1 | 1964 | 2594 | 0.010 |
Why?
|
| Electrodes | 1 | 1972 | 614 | 0.010 |
Why?
|
| Hindlimb | 1 | 1971 | 510 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1977 | 1805 | 0.010 |
Why?
|
| Creatine | 1 | 1971 | 426 | 0.010 |
Why?
|
| Nervous System | 1 | 1972 | 543 | 0.010 |
Why?
|
| Respiratory System | 1 | 1972 | 554 | 0.010 |
Why?
|
| Chromium Isotopes | 1 | 1968 | 29 | 0.000 |
Why?
|
| Iodine Isotopes | 1 | 1968 | 86 | 0.000 |
Why?
|
| Vena Cava, Superior | 1 | 1969 | 197 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 375 | 0.000 |
Why?
|
| Television | 1 | 1971 | 409 | 0.000 |
Why?
|
| Uterus | 1 | 1972 | 651 | 0.000 |
Why?
|
| Surface Tension | 1 | 1968 | 43 | 0.000 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1968 | 144 | 0.000 |
Why?
|
| Strontium | 1 | 1967 | 21 | 0.000 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 1970 | 218 | 0.000 |
Why?
|
| Infant, Newborn | 4 | 1968 | 26168 | 0.000 |
Why?
|
| Hospitals | 1 | 2001 | 3929 | 0.000 |
Why?
|
| Boston | 1 | 1980 | 9282 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1977 | 2143 | 0.000 |
Why?
|
| Phosphates | 1 | 1971 | 771 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1988 | 574 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1968 | 490 | 0.000 |
Why?
|
| Tourniquets | 1 | 1968 | 110 | 0.000 |
Why?
|
| Fluoroscopy | 1 | 1971 | 943 | 0.000 |
Why?
|
| Wound Healing | 1 | 1978 | 2786 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 2 | 1968 | 1570 | 0.000 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1970 | 316 | 0.000 |
Why?
|
| Rupture | 1 | 1968 | 443 | 0.000 |
Why?
|
| Cineradiography | 1 | 1965 | 22 | 0.000 |
Why?
|
| Fellowships and Scholarships | 1 | 1975 | 1118 | 0.000 |
Why?
|
| Skin Tests | 1 | 1968 | 637 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1968 | 532 | 0.000 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 1965 | 11 | 0.000 |
Why?
|
| Melena | 1 | 1965 | 32 | 0.000 |
Why?
|
| Thoracic Surgical Procedures | 2 | 1962 | 347 | 0.000 |
Why?
|
| Hemorrhagic Disorders | 1 | 1965 | 35 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1988 | 956 | 0.000 |
Why?
|
| Mandelic Acids | 1 | 1965 | 46 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1985 | 143 | 0.000 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1986 | 221 | 0.000 |
Why?
|
| Hypoxanthine | 1 | 1984 | 28 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 36247 | 0.000 |
Why?
|
| Glucans | 2 | 1962 | 68 | 0.000 |
Why?
|
| Cardiography, Impedance | 1 | 1984 | 40 | 0.000 |
Why?
|
| Pulmonary Veins | 1 | 1970 | 745 | 0.000 |
Why?
|
| Adenosine Triphosphatases | 1 | 1968 | 833 | 0.000 |
Why?
|
| Endocarditis, Bacterial | 1 | 1968 | 445 | 0.000 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1973 | 1076 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1968 | 521 | 0.000 |
Why?
|
| Hemolysis | 1 | 1965 | 423 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1974 | 3039 | 0.000 |
Why?
|
| Serotonin | 1 | 1967 | 1041 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1968 | 1083 | 0.000 |
Why?
|
| Lung | 1 | 1981 | 9989 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1968 | 708 | 0.000 |
Why?
|
| Electric Stimulation Therapy | 1 | 1967 | 613 | 0.000 |
Why?
|
| Chromatin | 1 | 1973 | 2939 | 0.000 |
Why?
|
| Neurosurgery | 1 | 1967 | 670 | 0.000 |
Why?
|
| Hypothermia, Induced | 1 | 1966 | 758 | 0.000 |
Why?
|
| Endocrine Glands | 1 | 1960 | 101 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1968 | 4814 | 0.000 |
Why?
|
| Monitoring, Intraoperative | 1 | 1966 | 941 | 0.000 |
Why?
|
| Hypersensitivity | 1 | 1968 | 1159 | 0.000 |
Why?
|
| Homeostasis | 1 | 1970 | 3305 | 0.000 |
Why?
|
| Elapid Venoms | 1 | 1978 | 41 | 0.000 |
Why?
|
| Sarcolemma | 1 | 1978 | 65 | 0.000 |
Why?
|
| Erythrityl Tetranitrate | 1 | 1977 | 1 | 0.000 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1978 | 163 | 0.000 |
Why?
|
| Consciousness | 1 | 1983 | 601 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1978 | 174 | 0.000 |
Why?
|
| Respiratory Insufficiency | 1 | 1965 | 1228 | 0.000 |
Why?
|
| Punctures | 1 | 1957 | 367 | 0.000 |
Why?
|
| Sodium Chloride | 1 | 1977 | 596 | 0.000 |
Why?
|
| Microspheres | 1 | 1977 | 785 | 0.000 |
Why?
|
| Carbon | 1 | 1977 | 669 | 0.000 |
Why?
|
| Asthma | 1 | 1972 | 6167 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1976 | 1346 | 0.000 |
Why?
|
| Androsterone | 1 | 1970 | 14 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1978 | 2192 | 0.000 |
Why?
|
| Butyrates | 1 | 1970 | 169 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1978 | 2909 | 0.000 |
Why?
|
| Diet Therapy | 1 | 1970 | 151 | 0.000 |
Why?
|
| Intermittent Claudication | 1 | 1970 | 305 | 0.000 |
Why?
|
| Propylene Glycols | 1 | 1965 | 90 | 0.000 |
Why?
|